Akt is transferred to the nucleus of cells treated with apoptin, and it participates in apoptin-induced cell death

Cell Proliferation

Volumn 40, Issue 6, 2007, Pages 835-848

  Maddika, S ^a,b   Bay, G H ^a   Kroczak, T J ^a   Ande, S R ^a,b   Wiechec, E ^a,c,d   Gibson, S B ^a,b   Los, M ^a,b,e  

^a UNIVERSITY OF MANITOBA   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

^c INSTITUTE OF ONCOLOGY   (Poland)

^d AARHUS UNIVERSITY   (Denmark)

^e BioApplications Enterprises Winnipeg   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

APOPTIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN P85;

ARTICLE; CELL DEATH; CELL NUCLEUS; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN TRANSPORT;

1-PHOSPHATIDYLINOSITOL 3-KINASE; CAPSID PROTEINS; CELL DEATH; CELL LINE, TUMOR; CELL NUCLEUS; ENZYME ACTIVATION; HUMANS; PROTEIN BINDING; PROTEIN TRANSPORT; PROTO-ONCOGENE PROTEINS C-AKT;

EID: 36248987708     PISSN: 09607722     EISSN: 13652184     Source Type: Journal    
DOI: 10.1111/j.1365-2184.2007.00475.x     Document Type: Article

References (52)

1. Ahn JY, Liu X, Liu Z, Pereira L, Cheng D, Peng J, Wade PA, Hamburger AW, Ye K (2006) Nuclear Akt associates with PKC-phosphorylated Ebp1, preventing DNA fragmentation by inhibition of caspase-activated DNase. EMBO J. 25, 2083 2095.
2. Aki T, Yamaguchi K, Fujimiya T, Mizukami Y (2003) Phosphoinositide 3-kinase accelerates autophagic cell death during glucose deprivation in the rat cardiomyocyte-derived cell line H9c2. Oncogene 22, 8529 8535.
3. Alvisi G, Poon IK, Jans DA (2006) Tumor-specific nuclear targeting: promises for anti-cancer therapy? Drug Resist. Updat. 9, 40 50.
4. Barkett M, Gilmore TD (1999) Control of apoptosis by Rel/NF-kappaB transcription factors. Oncogene 18, 6910 6924.
5. Baudino TA, Maclean KH, Brennan J, Parganas E, Yang C, Aslanian A, Lees JA, Sherr CJ, Roussel MF, Cleveland JL (2003) Myc-mediated proliferation and lymphomagenesis, but not apoptosis, are compromised by E2f1 loss. Mol. Cell 11, 905 914.
6. Brown L, Benchimol S (2006) The involvement of MAPK signaling pathways in determining the cellular response to p53 activation: cell cycle arrest or apoptosis. J. Biol. Chem. 281, 3832 3840.
7. Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS, Anderson MJ, Arden KC, Blenis J, Greenberg ME (1999) Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 96, 857 868.
8. Cantley LC (2002) The phosphoinositide 3-kinase pathway. Science 296, 1655 1657.
9. Coffer PJ, Jin J, Woodgett JR (1998) Protein kinase B (c-Akt): a multifunctional mediator of phosphatidylinositol 3-kinase activation. Biochem. J. 335, 1 13.
10. Cory S, Adams JM (2002) The Bcl2 family: regulators of the cellular life-or-death switch. Nat. Rev. Cancer 2, 647 656.
11. Danen-Van Oorschot AA, Zhang YH, Leliveld SR, Rohn JL, Seelen MC, Bolk MW, Van Zon A, Erkeland SJ, Abrahams JP, Mumberg D, Noteborn MH (2003) Importance of nuclear localization of apoptin for tumor-specific induction of apoptosis. J. Biol. Chem. 278, 27729 27736.
12. Downward J (2003) Targeting RAS signalling pathways in cancer therapy. Nat. Rev. Cancer 3, 11 22.
13. Fruman DA, Meyers RE, Cantley LC (1998) Phosphoinositide kinases. Annu. Rev. Biochem. 67, 481 507.
14. Fruman DA, Rameh LE, Cantley LC (1999) Phosphoinositide binding domains: embracing 3-phosphate. Cell 97, 817 820.
15. Fujio Y, Guo K, Mano T, Mitsuuchi Y, Testa JR, Walsh K (1999) Cell cycle withdrawal promotes myogenic induction of Akt, a positive modulator of myocyte survival. Mol. Cell. Biol. 19, 5073 5082.
16. Ghavami S, Barczyk K, Maddika S, Vogl T, Steinmüller L, Pour- Jafari H, Evans JA, Los M (2005) Monitoring of programmed cell death in vivo and in vitro - new and old methods of cancer therapy assessment. In : Los M, Gibson SB, eds. Apoptotic Pathways as Target for Novel Therapies in Cancer and Other Diseases. New York : Springer Academic Press, pp. 323 341.
17. Henriksson M, Luscher B (1996) Proteins of the Myc network: essential regulators of cell growth and differentiation. Adv. Cancer Res. 68, 109 182.
18. Hueber AO, Zornig M, Lyon D, Suda T, Nagata S, Evan GI (1997) Requirement for the CD95 receptor-ligand pathway in c-Myc-induced apoptosis. Science 278, 1305 1309.
19. Kauffmann-Zeh A, Rodriguez-Viciana P, Ulrich E, Gilbert C, Coffer P, Downward J, Evan G (1997) Suppression of c-Myc-induced apoptosis by Ras signalling through PI (3) K and PKB. Nature 385, 544 548.
20. Li Y, Dowbenko D, Lasky LA (2002) AKT/PKB phosphorylation of p21Cip/WAF1 enhances protein stability of p21Cip/WAF1 and promotes cell survival. J. Biol. Chem. 277, 11352 11361.
21. Lin B, Kolluri SK, Lin F, Liu W, Han YH, Cao X, Dawson MI, Reed JC, Zhang XK (2004) Conversion of Bcl-2 from protector to killer by interaction with nuclear orphan receptor Nur77/TR3. Cell 116, 527 540.
22. Liu X, Marengere LE, Koch CA, Pawson T (1993) The v-Src SH3 domain binds phosphatidylinositol 3′-kinase. Mol. Cell. Biol. 13, 5225 5232.
23. Los M, Schenk H, Hexel K, Baeuerle PA, Droge W, Schulze-Osthoff K (1995a) IL-2 gene expression and NF-kappa B activation through CD28 requires reactive oxygen production by 5-lipoxygenase. EMBO J. 14, 3731 3740.
24. Los M, Stroh C, Janicke RU, Engels IH, Schulze-Osthoff K (2001) Caspases: more than just killers? Trends Immunol. 22, 31 34.
25. Los M, Van de Craen M, Penning LC, Schenk H, Westendorp M, Baeuerle PA, Droge W, Krammer PH, Fiers W, Schulze-Osthoff K (1995b) Requirement of an ICE/CED-3 protease for Fas/APO-1-mediated apoptosis. Nature 375, 81 83.
26. Luo Z, Fujio Y, Kureishi Y, Rudic RD, Daumerie G, Fulton D, Sessa WC, Walsh K (2000) Acute modulation of endothelial Akt/PKB activity alters nitric oxide-dependent vasomotor activity in vivo. J. Clin. Invest. 106, 493 499.
27. Luo J, Manning BD, Cantley LC (2003) Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell 4, 257 262.
28. Maddika S, Ande SR, Panigrahi S, Paranjothy T, Weglarczyk K, Zuse A, Eshraghi M, Manda KD, Wiechec E, Los M (2007) Cell survival, cell death and cell cycle pathways are interconnected: implications for cancer therapy. Drug Resist. Updat. 10, 13 29.
29. Maddika S, Booy EP, Johar D, Gibson SB, Ghavami S, Los M (2005) Cancer-specific toxicity of apoptin is independent of death receptors but involves the loss of mitochondrial membrane potential and the release of mitochondrial cell-death mediators by a Nur77-dependent pathway. J. Cell Sci. 118, 4485 4493.
30. Maddika S, Mendoza FJ, Hauff K, Zamzow CR, Paranjothy T, Los M (2006) Cancer-selective therapy of the future: apoptin and its mechanism of action. Cancer Biol. Ther. 5, 10 19.
31. Marte BM, Downward J (1997) PKB/Akt: connecting phosphoinositide 3-kinase to cell survival and beyond. Trends Biochem. Sci. 22, 355 358.
32. Nimbalkar D, Henry MK, Quelle FW (2003) Cytokine activation of phosphoinositide 3-kinase sensitizes hematopoietic cells to cisplatin-induced death. Cancer Res. 63, 1034 1039.
33. Pekarsky Y, Hallas C, Palamarchuk A, Koval A, Bullrich F, Hirata Y, Bichi R, Letofsky J, Croce CM (2001) Akt phosphorylates and regulates the orphan nuclear receptor Nur77. Proc. Natl. Acad. Sci. USA 98, 3690 3694.
34. Pelengaris S, Khan M, Evan G (2002a) c-MYC: more than just a matter of life and death. Nat. Rev. Cancer 2, 764 776.
35. Pelengaris S, Khan M, Evan GI (2002b) Suppression of Myc-induced apoptosis in beta cells exposes multiple oncogenic properties of Myc and triggers carcinogenic progression. Cell 109, 321 334.
36. Pleiman CM, Hertz WM, Cambier JC (1994) Activation of phosphatidylinositol-3′ kinase by Src-family kinase SH3 binding to the p85 subunit. Science 263, 1609 1612.
37. Poon IK, Oro C, Dias MM, Zhang J, Jans DA (2005a) Apoptin nuclear accumulation is modulated by a CRM1-recognized nuclear export signal that is active in normal but not in tumor cells. Cancer Res. 65, 7059 7064.
38. Poon IK, Oro C, Dias MM, Zhang JP, Jans DA (2005b) A tumor cell-specific nuclear targeting signal within chicken anemia virus VP3/apoptin. J. Virol. 79, 1339 1341.
39. Prasad KV, Janssen O, Kapeller R, Raab M, Cantley LC, Rudd CE (1993) Src-homology 3 domain of protein kinase p59fyn mediates binding to phosphatidylinositol 3-kinase in T cells. Proc. Natl. Acad. Sci. USA 90, 7366 7370.
40. Rameh LE, Cantley LC (1999) The role of phosphoinositide 3-kinase lipid products in cell function. J. Biol. Chem. 274, 8347 8350.
41. Rohn JL, Zhang YH, Aalbers RI, Otto N, Den Hertog J, Henriquez NV, Van De Velde CJ, Kuppen PJ, Mumberg D, Donner P, Noteborn MH (2002) A tumor-specific kinase activity regulates the viral death protein Apoptin. J. Biol. Chem. 277, 50820 50827.
42. Shiraishi I, Melendez J, Ahn Y, Skavdahl M, Murphy E, Welch S, Schaefer E, Walsh K, Rosenzweig A, Torella D, Nurzynska D, Kajstura J, Leri A, Anversa P, Sussman MA (2004) Nuclear targeting of Akt enhances kinase activity and survival of cardiomyocytes. Circ. Res. 94, 884 891.
43. Song G, Ouyang G, Bao S (2005) The activation of Akt/PKB signaling pathway and cell survival. J. Cell. Mol. Med. 9, 59 71.
44. Stein RC (2001) Prospects for phosphoinositide 3-kinase inhibition as a cancer treatment. Endocr. Relat. Cancer 8, 237 248.
45. Subramanian T, Chinnadurai G (2003) Pro-apoptotic activity of transiently expressed BCL-2 occurs independent of BAX and BAK. J. Cell. Biochem. 89, 1102 1114.
46. 2/M arrest and apoptosis in the absence of p53. Genes Dev. 18, 1952 1957.
47. Trotman LC, Alimonti A, Scaglioni PP, Koutcher JA, Cordon-Cardo C, Pandolfi PP (2006) Identification of a tumour suppressor network opposing nuclear Akt function. Nature 441, 523 527.
48. Vanhaesebroeck B, Alessi DR (2000) The PI3K-PDK1 connection: more than just a road to PKB. Biochem. J. 346 (Part 3 561 576.
49. Vanhaesebroeck B, Waterfield MD (1999) Signaling by distinct classes of phosphoinositide 3-kinases. Exp. Cell Res. 253, 239 254.
50. Vivanco I, Sawyers CL (2002) The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat. Rev. Cancer 2, 489 501.
51. Workman P (2004) Inhibiting the phosphoinositide 3-kinase pathway for cancer treatment. Biochem. Soc. Trans. 32, 393 396.
52. Zheng Y, Bagrodia S, Cerione RA (1994) Activation of phosphoinositide 3-kinase activity by Cdc42Hs binding to p85. J. Biol. Chem. 269, 18727 18730.